Cargando…

CD137-CD137L Interaction Regulates Atherosclerosis via Cyclophilin A in Apolipoprotein E-Deficient Mice

BACKGROUND: Our previous studies showed that increased levels of cyclophilin A (CyPA) may be a valuable marker for predicting the severity of acute coronary syndromes and that interruption of CD137-CD137L interactions diminished the formation and progression of atherosclerosis in apolipoprotein E-de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuefeng, Yan, Jinchuan, Wu, Chao, Wang, Zhongqun, Yuan, Wei, Wang, Dongqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919780/ https://www.ncbi.nlm.nih.gov/pubmed/24520398 http://dx.doi.org/10.1371/journal.pone.0088563

Ejemplares similares

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

The Roles of CD137 Signaling in Atherosclerosis
por: Jung, In-Hyuk, et al.
Publicado: (2016)

Activation of CD137 Signaling Promotes Angiogenesis in Atherosclerosis via Modulating Endothelial Smad1/5‐NFATc1 Pathway
por: Weng, Jiayi, et al.
Publicado: (2017)

Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
por: Kwon, Byungsuk
Publicado: (2015)

CD137 Regulates NFATc1 Expression in Mouse VSMCs through TRAF6/NF-κB p65 Signaling Pathway
por: Yan, Jinchuan, et al.
Publicado: (2015)

The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus
por: Mak, Anselm, et al.
Publicado: (2019)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Exosome derived from CD137‐modified endothelial cells regulates the Th17 responses in atherosclerosis
por: Xu, Liangjie, et al.
Publicado: (2020)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Publicado: (2023)

Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E–deficient mice
por: Nigro, Patrizia, et al.
Publicado: (2011)

Increased Soluble CD137 Levels and CD4+ T‐Cell‐Associated Expression of CD137 in Acute Atherothrombotic Stroke
por: He, Yang, et al.
Publicado: (2018)

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
por: Luu, Khang, et al.
Publicado: (2021)

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity
por: Choi, Beom K., et al.
Publicado: (2020)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome
por: Yan, Jinchuan, et al.
Publicado: (2013)

CD137(+) T-Cells: Protagonists of the Immunotherapy Revolution
por: Ugolini, Alessio, et al.
Publicado: (2021)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Contributions of Costimulatory Molecule CD137 in Endothelial Cells
por: Yuan, Wei, et al.
Publicado: (2021)

CD137L, a driver of harmful inflammation in the nervous system
por: Wong, Hiu Yi, et al.
Publicado: (2023)

Identification of CD137-Expressing B Cells in Multiple Sclerosis Which Secrete IL-6 Upon Engagement by CD137 Ligand
por: Wong, Hiu Yi, et al.
Publicado: (2020)

CD6 expression has no effect on atherosclerosis in apolipoprotein E-deficient mice
por: Han, Juying, et al.
Publicado: (2018)

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
por: Chu, Dinh-Toi, et al.
Publicado: (2019)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

CD137 expression in cancer cells: regulation and significance
por: Glorieux, Christophe, et al.
Publicado: (2019)

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
por: Zeng, Qun, et al.
Publicado: (2019)

CD137 Facilitates the Resolution of Acute DSS-Induced Colonic Inflammation in Mice
por: Martínez Gómez, Julia M., et al.
Publicado: (2013)

Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway
por: Li, Bo, et al.
Publicado: (2020)

Contribution of CD137L to Sensory Hypersensitivity in a Murine Model of Neuropathic Pain
por: Wakley, Alexa A., et al.
Publicado: (2018)

Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs
por: Zeng, Qun, et al.
Publicado: (2019)

Correction: CD137 Facilitates the Resolution of Acute DSS-Induced Colonic Inflammation in Mice
por: Martínez Gómez, Julia M., et al.
Publicado: (2014)

Inhaled Asbestos Exacerbates Atherosclerosis in Apolipoprotein E–Deficient Mice via CD4(+) T Cells
por: Fukagawa, Naomi K., et al.
Publicado: (2008)

Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma
por: Cui, Xiangli, et al.
Publicado: (2013)

MiR-137 Deficiency Causes Anxiety-Like Behaviors in Mice
por: Yan, Hai-Liang, et al.
Publicado: (2019)

Species Difference of CD137 Ligand Signaling in Human and Murine Monocytes
por: Tang, Qianqiao, et al.
Publicado: (2011)

Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand
por: Kwon, Byungsuk
Publicado: (2012)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013)

Role of ADAM10 and ADAM17 in Regulating CD137 Function
por: Seidel, Jana, et al.
Publicado: (2021)

Soluble CD137 as a potential biomarker for severe COVID-19
por: Marques, Mariana de Oliveira, et al.
Publicado: (2022)

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
por: Adler, Adam J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d5i701huqsah2fg1nhvjnejuoo